What’s New at 4D Path

FDA Grants Breakthrough Designation to 4D Path for Novel Cancer Diagnostic Solution

Potential for a New Standard of Care to Improve Diagnostic Accuracy for Breast Cancer Exclusively from H&E Biopsy/Resection Images

Newton, Massachusetts, November 18, 2020 — 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its first software-as-a-medical-device solution. The 4D Q-plasia OncoReader Breast provides...

READ MORE


April 15, 2021
4D Path Prepping FDA Submission for AI-Enabled Breast Cancer Digital Pathology Product
March 16, 2021
4D Path, University of Leeds Extend Contract to Collaboratively Validate New Technology to Help Doctors More Accurately Diagnose Breast Cancer
December 15, 2020
Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path
December 2, 2020
FDA Gives Breakthrough Device Status to 4D Path’s Breast Cancer Diagnostic Platform
November 12, 2020
4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images
September 24, 2020
4D Path at Precision Medicine Leaders Summit’s Virtual Series on Precision Diagnostics
4D Path at Precision Medicine Leaders Summit’s Virtual Series on Precision Diagnostics
February 12, 2020
4D Path Adds New Processing Capabilities to Algorithm for Dramatically Accelerated Precise Cancer Diagnosis
January 14, 2020
4D Path Secures First Action Allowance Patent to Process Digital Whole Slide Images
December 15, 2019
4D Path Makes Continued Investments in Robust IT Infrastructure for Novel Precision Oncology Platform
December 10, 2019
4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M